Journal
NATURE MEDICINE
Volume 21, Issue 1, Pages 81-85Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3773
Keywords
-
Funding
- Worldwide Cancer Research [14-0321]
- PhD Fellowship Program of Boehringer Ingelheim Fonds-Foundation
- Dutch Cancer Society [UVA 2010-4822, NKI 2012-5463, UL 2012-5544]
- Wellcome Trust Research Training Fellowship for Clinicians
- Wellcome Trust [WT098051]
- Anticancer Fund
- K.G. Jebsen Foundation
- EU
- Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant
Ask authors/readers for more resources
Tumor-specific neo-antigens that arise as a consequence of mutations(1,2) are thought to be important for the therapeutic efficacy of cancer immunotherapies(3-5). Accumulating evidence suggests that neo-antigens may be commonly recognized by intratumoral CD8(+) T cells(3-7), but it is unclear whether neoantigen-specific CD4(+) T cells also frequently reside within human tumors. In view of the accepted role of tumor-specific CD4(+) T-cell responses in tumor control(8-10), we addressed whether neo-antigen-specific CD4(+) T-cell reactivity is a common property in human melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available